Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel Therapeutic Tumor Vaccines in Advanced Solid Tumors
NCT07567222Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Vaccines & Immunotherapeutics, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of YMN101, YMN102, YMN103, YMN104, YMN105 and 3 more in osteosarcoma (OS), pancreatic cancer (PC), head and neck squamous cell carcinoma (HNSCC) and 4 more (9 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Dose-Limiting Toxicities at 42 days and Adverse Events at 6 months. Started Jun 2026; status: recruiting.
02
Drugs
YMN101YMN102YMN103YMN104YMN105
03
Conditions
osteosarcoma (OS)pancreatic cancer (PC)head and neck squamous cell carcinoma (HNSCC)colon cancerhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07567222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07567222.